Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Norwegian clinical-stage biotech Nykode Therapeutics revealed that it has received notification from Genentech, a US ...

AlloVir has been reeling ever since a trio of phase 3 trial failures last year led the company to shed almost all of its staff. | AlloVir has been reeling after a trio of phase 3 trial failures last ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Biotech hedge fund investors are much smarter ... Furthermore, as firms like Genentech (now Roche; Basel), Imclone (now Eli Lilly, Indianapolis) and Wyeth (now Pfizer; New York) are acquired ...

The biotech believes that azelaprag can amplify ... The company has also announced the appointment of former Genentech and Alladapt Immunotherapeutics executive Dana McClintock as chief medical ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to improving vision in the real world through ...

Good day and welcome to Adaptive Biotechnologies third quarter financial results. (Operator Instructions) As a reminder, this call may be recorded. I would like to turn the call over to Karina ...

Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and ...